Expertise in
9
conditions

Dr. Peng Wang

Internal Medicine
Ohio State University Hospital-Pavilion
300 W 10th Ave, 
Columbus, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
9
conditions
Ohio State University Hospital-Pavilion
300 W 10th Ave, 
Columbus, OH 

Overview

Peng Wang is a primary care provider, practicing in Internal Medicine in Columbus, Ohio.

Dr. Wang is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Penile Cancer, WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, Muscle Invasive Bladder Cancer, and Endoscopy.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 15 clinical trials. Dr. Wang is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Internal Medicine in KY

Hospital Affiliations

University Of Kentucky Hospital
Ohio State University State Health System

Languages Spoken

English
Mandarin

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Ohio State University Hospital-Pavilion
300 W 10th Ave, Columbus, OH 43210

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 2
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers With Response and Resistance
A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers With Response and Resistance
Enrollment Status: Completed
Publish Date: August 11, 2026
Intervention Type: Other, Drug
Study Drug: Ibrutinib
Study Phase: Phase 2
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Gemcitabine Hydrochloride, Pembrolizumab
Study Phase: Phase 2
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2026
Intervention Type: Drug
Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone
Study Phase: Phase 2
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors With DNA-Repair Defects
A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors With DNA-Repair Defects
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2026
Intervention Type: Procedure, Drug
Study Drug: Olaparib
Study Phase: Phase 2
View 9 Less Clinical Trials

1 Total Publications

Saikosaponin A Inhibits Growth of Human Bladder Carcinoma T24 and 5637 Cells Both in Vitro and in Vivo.
Saikosaponin A Inhibits Growth of Human Bladder Carcinoma T24 and 5637 Cells Both in Vitro and in Vivo.
Journal: Biological & pharmaceutical bulletin
Published: May 01, 2022
Similar Doctors
Expertise in
14
conditions
Dr. Gregory A. Otterson
Internal Medicine
Expertise in
14
conditions
Dr. Gregory A. Otterson
Internal Medicine

The Osuccc-James

460 W 10th Ave, 
Columbus, OH 
 (0.2 miles away)
800-293-5066
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Gregory Otterson is a primary care provider, practicing in Internal Medicine in Columbus, Ohio. Dr. Otterson is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and Tissue Biopsy. Dr. Otterson is currently accepting new patients.

Expertise in
18
conditions
Dr. Lindsay M. Castle
Internal Medicine
Expertise in
18
conditions
Dr. Lindsay M. Castle
Internal Medicine

Mehl Foot And Ankle LLC

3525 Olentangy River Rd Ste 6300, 
Columbus, OH 
 (3.9 miles away)
614-566-3150
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Lindsay Castle is a primary care provider, practicing in Internal Medicine in Columbus, Ohio. Dr. Castle is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Heart Failure, Pulmonary Edema, Heart Failure with Preserved Ejection Fraction (HFpEF), Cardiac Ablation, and Pacemaker Implantation. Dr. Castle is currently accepting new patients.

Expertise in
15
conditions
Dr. James N. Allen
Internal Medicine
Expertise in
15
conditions
Dr. James N. Allen
Internal Medicine

Osu Neuroscience Center LLC

2050 Kenny Rd, 
Columbus, OH 
 (1.0 miles away)
614-293-4925
Languages Spoken:
English
See accepted insurances
Accepting New Patients

James Allen is a primary care provider, practicing in Internal Medicine in Columbus, Ohio. Dr. Allen is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Acute Interstitial Pneumonia, Interstitial Lung Disease, Pulmonary Fibrosis, and Pneumonia. Dr. Allen is currently accepting new patients.

Frequently Asked Questions about Dr. Peng Wang

How do I make an appointment with Dr. Peng Wang?

You can book an appointment with Dr. Peng Wang by calling their office at 614-366-7744. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Peng Wang a top-rated expert for Penile Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Peng Wang is classified as an Distinguished expert for Penile Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Peng Wang specialize in?

While Dr. Peng Wang is a Internal Medicine, they have specific expertise in Penile Cancer, WT1-Related Wilms Tumor Syndromes, and Chromophobe Renal Cell Carcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Peng Wang participate in research or clinical trials?

Yes. Dr. Peng Wang has published 1 articles and abstracts on conditions like Penile Cancer. You can view a list of Dr. Peng Wang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Peng Wang accept my insurance?

Dr. Peng Wang accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 614-366-7744 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wang's expertise for a condition
ConditionClose
    View All 10 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile